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Abstract
Background: The desired outcome of cancer vaccination is to induce a potent T cell response
which can specifically recognize and eliminate autologous tumor cells in vivo. Accordingly,
immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be
more clinically relevant than assays that demonstrate recognition of tumor protein or peptide
(antigen-specific).
Methods: Towards this goal, we adapted the IFN-γ ELISPOT assay to measure immune responses
against autologous primary tumor cells in vaccinated cancer patients. As a model system to develop
the assay, we utilized peripheral blood mononuclear cells (PBMC) directly isolated from follicular
lymphoma patients vaccinated with tumor-derived idiotype protein.
Results: After optimizing several variables, we demonstrated that the modified IFN-γ ELISPOT
assay could be used to reliably and reproducibly determine the tumor-reactive T cell frequency in
the PBMC of these patients. The precursor frequency of tumor-reactive T cells was significantly
higher in the postvaccine PBMC, compared with prevaccine samples in all patients tested.
Furthermore, the specificity of these T cells was established by the lack of reactivity against
autologous normal B cells.
Conclusions:  These results demonstrate the feasibility of quantitating tumor-specific T cell
responses when autologous, primary tumor cells are available as targets.
Introduction
Active specific immunotherapy is a promising but investi-
gational modality in the management of cancer patients.
Currently, several different cancer vaccine formulations
such as peptides, proteins, antigen-pulsed dendritic cells,
whole tumor cells, etc. in combination with various adju-
vants and carriers are being evaluated in clinical trials [1-
3]. To determine the optimal cancer vaccine strategy, a
surrogate immunological end-point that correlates with
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clinical outcome needs to be defined since it would facil-
itate the rapid comparison of these various formulations.
The clinical efficacy of cancer vaccines is likely to depend
on several factors. Firstly, the induced T cells should rec-
ognize tumor antigens that are naturally processed and
presented in the context of MHC class I and class II mole-
cules on the surface of the tumor. Hence, an immunolog-
ical assay that demonstrates recognition of native tumor
(tumor-specific) may be a more clinically relevant assay to
assess T cell responses following cancer vaccination, com-
pared with assays that demonstrate recognition of tumor
protein or peptide presented on appropriate antigen-pre-
senting cells (antigen-specific). Secondly, the functional
quality and the magnitude of the induced anti-tumor T
cell responses are critical for the successful eradication of
cancer. Therefore, it is conceivable that an immunological
assay that directly measures both the function and fre-
quency of the induced tumor-specific T cells could poten-
tially serve as a surrogate end-point for cancer vaccine
trials.
Traditional immunological assays such as ELISA, prolifer-
ation and cytotoxicity assays can detect immune
responses in vaccinated patients but are unable to quanti-
tate individual reactive cells. In contrast, novel assays such
as ELISPOT assay, intracellular cytokine assay and
tetramer assay can quantitate the frequency of antigen-
specific T cells. Of these, the ELISPOT assay is the most
sensitive with a general limit of detection of 1 × 105 PBMC
when tested with tumor antigens [4]. The assay detects
locally secreted cytokine molecules by means of antibody-
coated membranes to capture the secreted cytokine
derived from the productive interaction of the effector cell
and its target cell. The assay has gained increasing popu-
larity, especially as a surrogate measure for cytotoxic T
lymphocyte (CTL) responses because it is simple, reliable,
sensitive and quantitative [5,6]. However, the ELISPOT
assay has been primarily used for the detection of T cell
responses against vaccine components by using peptide or
protein pulsed antigen-presenting cells as surrogate T cell
targets [7-9]. Demonstration of reactivity to vaccine com-
ponents does not necessarily equate to recognition and
elimination of tumor cells.
Here, we report the development of a modified IFN-γ
ELISPOT assay for the direct quantitation of T cell
responses against autologous primary tumor cells. To
develop the assay, we used follicular lymphoma patients
vaccinated with tumor-derived idiotype (Id) protein as a
model, since we have previously shown that Id vaccina-
tion induces tumor-specific T cell responses in these
patients [10].
Methods
Patients
After obtaining signed informed consent, patients with
Stage III or IV follicular center cell lymphoma grade 1 or
grade 2 were enrolled on this investigational review
board-approved clinical trial. All patients underwent a
lymph node biopsy prior to starting treatment to obtain
tissue for vaccine production. The lymph node specimen
was processed into a single cell suspension and cryopre-
served. Patients were initially treated uniformly with a
chemotherapy regimen as described previously [10].
Vaccine formulation and administration
Tumor immunoglobulin protein, Id, was isolated from
each patient's tumor by heterohybridoma fusion [10]. The
appropriate fusions were identified by comparing the Ig
VH  CDR3 sequences of the fusions with the patient's
tumor. The Id was incorporated into liposomes along
with recombinant human IL-2 as described previously
[11]. Each dose of the vaccine was formulated on a per ml
basis with 2 mg of the patient-specific tumor-derived Id
protein, 4 × 106 IU of recombinant human IL-2 and 160
mg of dimyristoylphosphatidylcholine lipid (DMPC,
Biomira USA Inc., NJ) that was used to generate lipo-
somes. Approximately six months after the completion of
the chemotherapy, all patients were administered five
doses of the vaccine subcutaneously at months 0, 1, 2, 3
and 5.
Peripheral Blood Mononuclear Cells
Blood samples were obtained from patients at various
time points before and after vaccination. Peripheral blood
mononuclear cells (PBMC) were isolated by density gradi-
ent separation with Ficoll Isopaque (ICN Biomedicals
Inc., Aurora, OH) and cryopreserved for immunological
assays. Pre- and postvaccine PBMC were thawed, washed
and resuspended to a concentration of 1–3 × 106 cells/ml
in RPMI 1640 medium (Invitrogen Corp, Carlsbad, CA),
supplemented with 5% FBS (Hyclone, Logan, Utah), 1
mM sodium pyruvate (BioWhittaker, Walkersville, MD),
20 mM HEPES buffer (Invitrogen), 50 µM β-mercaptoeth-
anol (Sigma, St. Louis, MO), 2 mM L-glutamine, 100 U/
ml penicillin and 100 µg/ml streptomycin (Invitrogen)
(complete medium). Five ml of the cell suspensions were
plated into each well of 6 well plates (Corning, Inc. Corn-
ing, NY) and rested overnight at 37°C, 5% CO2. The next
day, PBMC were harvested, washed and cell viability was
assessed by trypan blue prior to use in the ELISPOT assay.
Activation of tumor cells and normal B cells
Cryopreserved cells from the lymph node biopsy speci-
men were enriched for tumor cells by depletion of T cells
with CD3 microbeads over a magnetic column (Miltenyi
Biotec, Auburn, CA) using the manufacturer's protocol.
Autologous normal B cells were isolated from PBMC byJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/9
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magnetic cell separation method using the B Cell Isola-
tion Kit (Miltenyi Biotec) according to the manufacturer's
protocol. The purity of the isolated tumor and normal B
cells was >95%. Tumor cells and normal B cells were acti-
vated for 3 days with 800 ng/ml of recombinant human
soluble CD40 ligand trimer (sCD40Lt, Amgen, Thousand
Oaks, CA) and recombinant human IL-4 (2 ng/ml)
(Peprotech, Rocky Hill, NJ). Activated tumor cells and
normal B cells were harvested and washed prior to co-cul-
ture with PBMC in the ELISPOT assay.
IFN-γ Enzyme-linked immunospot (ELISPOT) assay
MultiScreen-IP opaque 96-well plates (High Protein Bind-
ing Immobilon-P membrane, Millipore, Bedford, MA)
were coated overnight at room temperature with 50 µl/
well of 20 µg/ml mouse anti-human IFN-γ mAb (Bio-
Source, Camarillo, CA) in DPBS (Invitrogen). After over-
night incubation, the plates were washed three times with
200 µl DPBS/well and blocked with 200 µl/well of RPMI
1640, 10% human AB serum (Mediatech, Herndon, VA),
25 mM Hepes, 2 mM L-glutamine, 100 U/ml penicillin
and 100 µg/ml streptomycin (Invitrogen) for 2 h at 37°C,
5% CO2. Harvested effectors were added to the plates in
triplicates at 1 × 105 cells/well with either culture medium
alone or with 2 × 105 cells/well sCD40Lt activated autolo-
gous tumor cells and cultured for 48 h at 37°C, 5% CO2.
The plates were washed manually 6 times with 200 µl/
well of DPBS/0.05% Tween. 50 µl/well of 2 µg/ml mouse
anti-human IFN-γ-biotinylated mAb (BD Pharmingen,
San Diego, Ca) in DPBS/1%BSA/0.05% Tween was added
and the plates were incubated for 2 h at room tempera-
ture. Plates were manually washed 4 times with DPBS and
50 µl/well of streptavidin HRP (BD Pharmingen) diluted
1:2000 in DPBS/1% BSA was added for 1 h at room tem-
perature. The plates were washed a final 4 times with
DPBS. Spots were visualized by adding 100 µl/well of
TrueBlue™ Peroxidase Substrate (KPL, Gaithersburg, MD)
for 2 min. Plates were scanned and counted using the
ImmunoSpot analyzer (Cellular Technology, Ltd., Cleve-
land, OH) to determine the number of spots/well. The
precursor frequency of tumor-specific T cells was deter-
mined by subtracting the background spots in tumor
alone and PBMC alone from the number of spots seen in
response to tumor cells.
Statistical analysis
Statistical analysis was performed using Student's t-test for
paired mean values and Pearson correlation coefficient
(R2).
Results
Optimization of tumor IFN-γ ELISPOT assay
As a model system to develop a tumor IFN-γ ELISPOT
assay, PBMC from follicular lymphoma patients vacci-
nated against an autologous tumor antigen (Id) were used
as effectors, and primary autologous lymphoma tumor
cells were used as targets. Several variables were evaluated
to optimize the signal to noise ratio for the detection and
quantitation of tumor-specific T cells. Table 1 summarizes
the assay conditions that were tested and selected for the
optimized autologous tumor IFN-γ ELISPOT assay. Varia-
bles that required optimization included type of micro-
titer plate, activation of tumor cells with sCD40Lt, freshly
thawed versus overnight cultured PBMC, effector to target
cell ratio, length of incubation time of the assay, culture
medium, and finally, substrate detection system.
Opaque plates were optimal for analysis of IFN-γ spots
Opaque and clear plastic versions of MultiScreen-IP ELIS-
POT plates were compared to facilitate optimal spot anal-
ysis using the ImmunoSpot analyzing system. The opaque
version was most advantageous for ELISPOT enumera-
tion. The opaque plastic precluded light-refraction from
the reader's light source and therefore eliminated altera-
tions in background color of individual wells that inter-
fered with the ability to correctly enumerate spots. The
ImmunoSpot analyzing system was able to auto-center
opaque, but not the clear plastic plates, thereby facilitated
automated analysis.
sCD40Lt activated tumor cells enhanced cytokine 
production by T cells
Activation of B cell tumor cells with sCD40Lt upregulated
various costimulatory molecules and MHC class I and
class II molecules on the surface of tumor cells associated
with enhanced antigen presenting capability [[12] and
Neelapu et al., manuscript submitted]. Our pilot experi-
ments indicated that activation of tumor cells with
sCD40Lt markedly enhanced the sensitivity of the ELIS-
POT assay by increasing the IFN-γ production by respond-
ing T cells as compared to unmodified tumor cells (data
not shown). We have therefore used sCD40Lt activated
tumor cells as stimulators to evaluate T cell responses in
this assay.
Resting PBMC overnight improved the reactivity of 
effector cells
To determine if resting in culture medium can improve
the functional capacity of the cryopreserved effectors, we
tested the reactivity of the PBMC against autologous
tumor cells after resting them either overnight or for 2 h.
Postvaccine PBMC showed markedly enhanced reactivity
against autologous tumor cells after the longer rest period.
Moreover, the precursor frequency of tumor-reactive T
cells in the postvaccine sample was significantly higher
than the prevaccine sample only after overnight resting (p
< 0.05). The lack of significant difference in the number of
IFN-γ spots in prevaccine PBMC between the two condi-
tions suggested that the longer resting did not increase
non-specific reactivity (Figure 1). Thus, these resultsJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/9
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implied that overnight resting of cryopreserved PBMC
markedly improved our ability to detect tumor-reactive T
cells by ELISPOT.
Effector to tumor cell ratio
To determine the optimal ratio of effector to tumor cells,
a checkerboard titration was performed. Regardless of the
Optimization of PBMC preparation for use in the tumor IFN-γ ELISPOT assay Figure 1
Optimization of PBMC preparation for use in the tumor IFN-γ ELISPOT assay. Cryoperserved PBMC were thawed 
and rested in culture medium either overnight (O/N) or for 2 h and assessed for optimal reactivity to tumor cells. Pre- (white 
columns) and postvaccine (grey columns) PBMC (1 × 105 cells/well) were co-cultured with sCD40Lt activated autologous 
tumor cells (2 × 105 cells/well) for 48 h in the ELISPOT assay. Significantly (p < 0.05) more IFN-γ production by responding T 
cells was observed in post- compared to prevaccine PBMC when PBMC were rested overnight. Data is presented as average 
number of spots per well ± SD and is representative of four experiments with similar results.
Table 1: Summary of assay conditions that were tested and selected for the autologous tumor IFN-γ ELISPOT assay
Item optimized Comparison Selected for assay
Plates Clear vs. Opaque Opaque
Targets (tumor cells) sCD40Lt stimulated vs. non-stimulated sCD40Lt stimulated
Effectors (PBMC) Overnight cultured vs 2 h cultured Overnight cultured cells
Effector:Tumor Ratio 100:100, 100:200, 100:300K 100:200K cells/well
200:100, 200:200, 200:300K
Incubation time of assay 24 and 48 hours 48 hour
Media 5% and 10% HuAB vs. 5% and 10% FBS 10% HuAB
Substrate Detection System AEC, TrueBlue™, and BCIP TrueBlue™
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effector to tumor ratio, the frequency of tumor-reactive T
cells was greater in postvaccine compared to prevaccine
samples. The best signal to noise ratio was achieved with
effector cells at 1 × 105 per well and tumor cells at 2 × 105
per well (Figure 2). Although reactivity to tumor cells was
observed in postvaccine samples at effector cell concentra-
tions ≥2 × 105 per well, the resulting ELISPOTs were too
numerous and/or diffuse to accurately enumerate the pre-
cursor frequency (data not shown). We have therefore
used 1 × 105 effector cells stimulated with 2 × 105 tumor
cells to evaluate T cell responses in this assay.
Longer assay incubation time detected higher number of 
tumor-reactive T cells
IFN-γ is normally produced de novo and secreted between
24–72 h after T cells interact with appropriate targets. In
our system, significantly (p < 0.05) more IFN-γ spots were
observed in postvaccine compared to prevaccine PBMC
samples regardless of the length of incubation. However,
the longer incubation of 48 h detected significantly (p <
0.01) higher numbers of tumor-reactive T cells in the post-
vaccine sample (Figure 3). Further incubation (72 h) did
not enhance the assay's ability to measure T cell responses
Optimization of effector to target cell ratio for use in the tumor IFN-γ ELISPOT assay Figure 2
Optimization of effector to target cell ratio for use in the tumor IFN-γ ELISPOT assay. Various concentrations of 
pre- (white columns) and postvaccine (grey columns) PBMC (1 × 105, 2 × 105 or 3 × 105 cells/well) were co-cultured with dif-
ferent concentrations of sCD40Lt activated autologous tumor cells (1 × 105, 2 × 105 or 3 × 105 cells/well) for 48 h in the ELIS-
POT assay. Cryoperserved PBMC were thawed and cultured overnight. Data for PBMC concentrations of 3 × 105 and 2 × 105 
cells/well are not shown because the resulting spots were too numerous and/or diffuse to count accurately. Significantly (p < 
0.01) more IFN-γ production by responding T cells was observed in post- compared to prevaccine PBMC samples regardless of 
the effector to target ratio. Moreover, significantly (p < 0.01) more tumor specific T cells were enumerated at the 100:200 
effector to target ratio compared to the other ratios tested. Data is presented as average number of spots per well ± SD and 
is representative of four experiments with similar results.
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(data not shown). The similar frequency of tumor-reactive
T cells in prevaccine samples at both 24 and 48 h of incu-
bation suggested that the longer incubation time did not
increase non-specific activity.
10% Human AB serum was optimal for culture medium
Our previous studies suggested that the type of serum can
influence the signal to noise ratio when analyzing anti-
gen-specific T cell responses by various in vitro immuno-
logical assays. We have therefore tested media containing
5% or 10% HuAB serum and 5% or 10% FBS to determine
the optimal sera for the tumor ELISPOT culture medium.
The greatest frequency of the tumor-reactive T cells could
be enumerated when medium containing 10% HuAB was
utilized. The 10% HuAB medium also yielded the most
significant (p < 0.001) difference between pre- and post-
vaccine T cell reactivity to tumors (Figure 4). Regardless of
the type of serum used, 10% media were superior to 5%
media (data not shown).
Substrate detection system
Several substrate detection systems were evaluated for
spot quality and signal to noise (stimulated to
unstimulated) ratio. Due to limited patient samples, the
color development system was first tested and optimized
using flu matrix peptide (FMP)-reactive PBMC from nor-
mal donors. PBMC (3 × 105 per well) alone and PBMC
stimulated with FMP (5 µg/ml, NH2-G-I-L-G-F-V-F-T-L-
COOH, American Peptide Company, Inc., Sunnyvale,
CA) were utilized in the ELISPOT assay. After incubation
for 24 h, spots were visualized using AEC (CALBIOCHEM,
San Diego, CA), BCIP/NBT (KPL, Gaithersburg, MD) and
Incubation of PBMC and tumor cells for 48 h enhanced the sensitivity of the tumor IFN-γ ELISPOT assay Figure 3
Incubation of PBMC and tumor cells for 48 h enhanced the sensitivity of the tumor IFN-γ ELISPOT assay. Pre- 
(white columns) and postvaccine (grey columns) PBMC (1 × 105 cells/well) were co-cultured with sCD40Lt activated autolo-
gous tumor cells (2 × 105 cells/well) for 24, 48 and 72 h in the ELISPOT assay. Significantly (p < 0.05) more IFN-γ production by 
responding T cells was observed in post- compared to prevaccine PBMC samples regardless of the length of incubation. More-
over, a significantly higher number of tumor-reactive T cells were observed at the 48 h in the postvaccine PBMC (p < 0.01). 
Data is represented as average number of spots per well ± SE (n = 3). Data for 72 h is not shown because the resulting spots 
were too numerous and/or diffuse to count accurately.
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TrueBlue™ (KPL) substrate detection systems according to
the manufacturer's instructions. Extensive checkerboard
titrations of the individual detection reagents (detecting
antibody and substrate) were performed to optimize each
system. The TrueBlue™ system was superior to AEC and
BCIP/NBT in spot quality (Figure 5). The TrueBlue™ sub-
strate was chosen as the optimal detecting system since it
produced distinct spots with minimal non-specific stain-
ing of the plate membrane. Similar results were observed
when PBMC were tested against autologous tumor cells
(Figure 6).
IFN-γ spots produced by pre- and postvaccine PBMC using 
the optimized assay
Based on preliminary testing, the protocol described in
the materials and methods was established as optimal
(Table 1). Triplicate wells demonstrating the IFN-γ spots
produced by pre- and postvaccine PBMC analyzed in
parallel from a representative patient are shown in Figure
6. A significantly higher number of IFN-γ spots were
detected in the postvaccine PBMC as compared to the pre-
vaccine sample (p < 0.001).
Reproducibility of the tumor IFN-γ ELISPOT assay
The optimized assay could reliably detect the presence of
tumor-reactive T cells in follicular lymphoma patients
immunized with liposomal Id/IL-2 vaccine (Figure 7).
The precursor frequency of the tumor-reactive T cells was
significantly (p ≤ 0.001) higher in the postvaccine PBMC
as compared to the prevaccine sample in all three patients.
To assess the reproducibility of the tumor ELISPOT assay,
the pre- and postvaccine PBMC samples from each of the
above three patients were tested blinded in three inde-
pendent experiments by three separate technicians. The
Medium containing HuAB serum enhanced the ability to measure tumor-reactive T cells Figure 4
Medium containing HuAB serum enhanced the ability to measure tumor-reactive T cells. Pre- (white columns) 
and postvaccine (grey columns) PBMC (1 × 105 cells/well) were co-cultured with sCD40Lt activated autologous tumor cells (2 
× 105 cells/well) for 48 h. The optimal media for the tumor IFN-γ ELISPOT assay was evaluated by comparing HuAB and FBS as 
the serum source. Although both HuAB and FBS containing media yielded significant (p < 0.001 and p < 0.05, respectively) dif-
ferences between pre- and postvaccine T cell reactivity to tumors, medium containing HuAB yielded significantly (p < 0.05) 
more IFN-γ production.
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results were very reproducible for all three patients with a
Pearson correlation coefficient (R2) above 0.9 for all
experiments (Figure 7). The results of the tumor ELISPOT
assay for these three patients also correlated with the
results of a cytokine induction assay when the IFN-γ level
in the supernatant was measured by ELISA (data not
shown).
Specificity of the tumor-reactive T cell responses
To test specificity of the T cell responses, postvaccine
PBMC were co-cultured with either sCD40Lt activated
autologous tumor cells or normal B cells in parallel. A
significant number of IFN-γ spots were detected only in
response to autologous tumor cells but not autologous
normal B cells in all three patients that were tested (p <
0.001, Figure 8).
Discussion
Our data demonstrate that the ELISPOT assay could be
easily adapted to reliably and reproducibly determine the
precursor frequency of tumor-specific T cells in follicular
lymphoma patients immunized with an autologous
tumor-derived Id vaccine. We have also been able to use a
modification (5 day tumor activation, 72 h incubation) of
this assay to quantitate the tumor-specific T cell responses
in mantle cell lymphoma patients vaccinated with Id
(data not shown). Thus, this assay fulfilled our stated
objectives for a clinically relevant immunological assay by
demonstrating that it could functionally (IFN-γ produc-
tion) and quantitatively assess the T cell responses
induced by a cancer vaccine against autologous primary
tumor cells.
As opposed to the traditional antigen-specific assays that
assess immune responses against vaccine components
(peptides or proteins), tumor-specific immunological
assays in addition to being more clinically relevant can
have several advantages. Firstly, tumor-specific assays can
potentially detect both CD4+ and CD8+ T cell responses
since endogenous antigens are presented by both MHC
class I molecules as well as MHC class II molecules [[13-
15] and Neelapu et al., manuscript submitted]. In con-
trast, antigen-specific (protein) assays detect mostly CD4+
T cell responses since the soluble exogenous antigen is
predominantly processed in the endosomal pathway and
presented on MHC class II molecules. Secondly, tumor-
specific assays can be used in patients with any HLA phe-
notype unlike peptide assays that are usually restricted to
Comparison of three different substrate detection systems  for the tumor IFN-γ ELISPOT assay Figure 5
Comparison of three different substrate detection 
systems for the tumor IFN-γ ELISPOT assay. The 
AEC, BCIP and TrueBlue™ substrate detection systems 
were evaluated for spot quality and signal to noise (stimu-
lated to unstimulated) ratio using flu matrix peptide (FMP)-
reactive PBMC from normal donors. PBMC (3 × 105 cells/
well) alone and stimulated with FMP (5 µg/ml) were run in 
the ELISPOT assay for 24 hr. Spots were visualized using 
AEC, BCIP/NBT and TrueBlue™ substrate detection sys-
tems according to the manufacturer's instructions. Images 
from the plate scan generated by the ImmunoSpot analyzing 
system are shown. Data is represented as average number of 
spots per well ± SD.
FMP
Representative wells of a tumor IFN-γ ELISPOT assay Figure 6
Representative wells of a tumor IFN-γ ELISPOT 
assay. Pre- and postvaccine PBMC (1 × 105 cells/well) were 
co-cultured with sCD40Lt activated autologous tumor cells 
(2 × 105 cells/well) for 48 h as described in Materials and 
Methods. Wells containing PBMC alone and tumor cells 
alone served as controls. Samples were tested blinded in 
triplicates. Images from the plate scan generated by the 
ImmunoSpot analyzing system are shown. Average numbers 
of spots per well are indicated. Data is from a representative 
experiment of nine with similar results.
Pre PBMC + Tumor (Ave. Spots = 4) Pre PBMC alone (Ave. Spots = 2)
Post PBMC alone (Ave. Spots = 7) Post PBMC + Tumor (Ave. Spots = 99)
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>Reproducibility of the tumor IFN-γ ELISPOT assay Figure 7
Reproducibility of the tumor IFN-γ ELISPOT assay. Pre- and postvaccine PBMC from three patients (P 1–3) were co-
cultured with autologous sCD40Lt activated tumor cells for 48 h as described in Materials and Methods. All samples were 
tested blinded in three independent experiments by three technicians. The numbers of spots per 1 × 105 effectors were signif-
icantly (p ≤ 0.001) higher in the postvaccine as compared to the prevaccine samples for all three patients. For each patient the 
data is presented as spots per 1 × 105 effector cells. The correlation of the results between technicians was highly significant 
(R2 above 0.9 for all experiments).
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a single HLA phenotype (e.g. HLA-A*0201) depending on
the binding affinity of the peptide. Thirdly, tumor-specific
assays allow monitoring of patients when whole or lysed
tumor cells are used as the immunogen and the tumor-
specific antigens have not been defined. Finally, tumor
recognition assays potentially enable the detection of
immune responses against the immunogen as well as
other antigens not represented in the vaccine. For
instance, they can detect immune responses against cryp-
tic epitopes that may develop by epitope spreading,
secondary to the inflammatory response initiated by T
cells specific against the immunogen [16,17].
A probable limitation for tumor recognition assays is the
availability of tumor cells. While primary tumor cells are
easily accessible for some cancers (e.g. lymphoma,
leukemia, myeloma, melanoma), they may not be
generally accessible for certain other cancers (e.g. breast
cancer, renal cell cancer). When available, it may be feasi-
ble to adapt the IFN-γ ELISPOT assay for the quantitative
assessment of T cell responses against primary tumor cells
as a preferable alternative to antigen-specific assays. Such
quantitative tumor-specific immunological assays need to
be eventually evaluated in large clinical trials to determine
their validity as surrogate end-points for clinical efficacy
of cancer vaccines.
Conclusions
We adapted the IFN-γ ELISPOT assay to directly measure
immune responses against autologous primary tumor
cells in vaccinated cancer patients. We demonstrated that
the modified IFN-γ ELISPOT assay could be used to
reliably and reproducibly determine the tumor-reactive T
cell frequency in the PBMC of these patients when
sCD40Lt activated tumor cells were used as targets. The
precursor frequency of tumor-reactive T cells was
significantly higher in the postvaccine PBMC, compared
with prevaccine samples in all patients tested. Further-
more, the specificity of these T cells was established by the
lack of reactivity against autologous normal B cells. These
results demonstrate the feasibility of quantitating tumor-
specific T cell responses when autologous, primary tumor
cells are available as targets.
Specificity of the tumor-reactive T cell responses Figure 8
Specificity of the tumor-reactive T cell responses. Postvaccine PBMC samples from three patients (P 1–3) were co-cul-
tured with either autologous sCD40Lt activated follicular lymphoma tumor cells (white columns) or activated normal B cells 
(gray columns) for 48 h. PBMC alone are shown in black columns. All samples were tested blinded. Average number of spots 
per 1 × 105 PBMC ± SE (n = 3) are shown.
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